Name: R411

---

Type: small molecule

---

Groups: investigational

---

Indication: Investigated for use/treatment in asthma.

---

Accession Number: DB05468 ( DB05468)

---

Description: R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to either a4b1 or a4b7.

---

Structure:

---

Prescription Products: Not Available

---

Generic Prescription Products: Not Available

---

Over the Counter Products: Not Available

---

International Brands

• No Brands

---

Brand Names

• No Brands

---

Brand Mixtures

Brand Name	Ingredients

Brand Name	Ingredients

---

Categories

• No Category

Indication: Investigated for use/treatment in asthma.

---

Pharmacodynamics: Not Available

---

Mechanism of action: R411 prevents binding of V-CAM1 to either a4b1 or a4b7.

---

Absorption: Not Available

---

Volume of distribution: Not Available

---

Protein binding: Not Available

---

Metabolism: Not Available

---

Route of elimination: Not Available

---

Half life: Not Available

---

Clearance: Not Available

---

Toxicity: Good safety profile observed in preclinical and clinical studies

---

Affected organisms

• Not Available

---

SNP Mediated Adverse Drug Reactions

• Not Available

Manufacturers:

• Not Available

---

Packagers:

• Not Available

---

Dosage forms

Form	Route	Strength

Form	Route	Strength

---

Prices

Unit description	Cost	Unit

Unit description	Cost	Unit

---

Patents

Country	Patent Number	Approved	Expires (estimated)

Drug Interactions

Drug	Interaction

Drug	Interaction

---

Food Interactions:

• Not Available

Kingdom: Not Available

---

Super Class: Not Available

---

Class: Not Available

---

Sub Class: Not Available

---

Direct Parent: Not Available

---

Alternative Parents:

• Not Available

---

substituent:

• Not Available

Synthesis Reference: Not Available

---

General Reference: # Hijazi Y, Welker H, Dorr AE, Frank K, Renzetti LM, Patel I: Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers. Eur J Clin Pharmacol. 2006 Jan;62(1):83-5. Epub 2005 Dec 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16369813 # Hijazi Y, Welker H, Dorr AE, Tang JP, Blain R, Renzetti LM, Abbas R: Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J Clin Pharmacol. 2004 Dec;44(12):1368-78. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15545307

---

External Links:

Resource	Link

Resource	Link

---

ATC Codes:

• Not Available

---

AHFS Codes:

• Not Available

---

MSDS: Download